Advanced Cell Technology Announces Collaboration with the Casey Eye Institute at Oregon Health and Science University
Feb 6 2007, 7:33 AM EST
Business Wire
Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced that it has entered into a sponsored research agreement with Oregon Health and Science University. The Company is collaborating with Dr. Raymond Lund, Dr. Richard Weleber and Dr. Peter Francis at the Casey Eye Institute to conduct preclinical studies for its Retinal Pigment Epithelium ("RPE") Program. Specifically, the research team is conducting a dosage study utilizing the Company's RPE cells in the Royal College of Surgeons ("RCS") rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. The Company is also in discussions with the Oregon Health and Science University team in regard to future plans for a Phase I human clinical trial.
Dr. Peter Francis, Assistant Professor of Ophthalmic Genetics and Co-Director of the Oregon Retinal Degeneration Center at the Casey Eye Institute said, "We are very excited to be working with Advanced Cell Technology. This area or research shows great promise for the treatment of a number of blinding conditions."
Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology responded, "We are very excited to be working with the entire team at the Casey Eye Institute. Drs. Lund, Weleber and Francis bring a wealth of experience to our program in the area of retinal degenerative disease. We are also honored to enter into our first collaboration with Oregon Health and Science University, which has clearly distinguished itself as a leader in biomedical research."
